Skip Navigation


Annals of Oncology Advance Access originally published online on June 9, 2006
Annals of Oncology 2006 17(12):1850-1851; doi:10.1093/annonc/mdl138
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/12/1850    most recent
mdl138v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Etienne-Grimaldi, M-C
Right arrow Articles by Milano, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Etienne-Grimaldi, M-C
Right arrow Articles by Milano, G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

letters to the editor

EGFR expression in colon cancer: a break in the clouds

M-C Etienne-Grimaldi1, A Cayre2, F Penault-Llorca2, M Francoual1, J-L Formento1, D Benchimol3, A Bourgeon3 and G Milano1,*

1 Centre Antoine-Lacassagne, Nice, France
2 Centre Jean-Perrin, Clermont Ferrand, Nice, France
3 Hôpital l'Archet, Nice, France

* (E-mail: gerard.milano@nice.fnclcc.fr)

The first 10% of the full text of this article appears below.

Advances in the understanding of tumor biology have led to the development of targeted therapies [1]. One of the most promising is the epidermal growth factor receptor (EGFR), a member of the subclass I of the transmembrane receptor tyrosine kinase super-family [2] which is overexpressed in different solid cancers, reaching up to 80% overexpression in colorectal cancer [3, 4]. We recently analyzed EGFR in 82 colorectal cancer samples, based on EGF binding, and showed that in the majority of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?